Skip navigation

Optimize Integration • Streamline Global Deployment • Ensure Compliance

December 12, 2017
  • Philadelphia, PA

As of June 30, 2017, the U.S. FDA extended the Product Identifier Requirements under the Drug Supply Chain Security Act (DSCSA) to November 26, 2018 due to lack of industry readiness. Join your peers this December at CBI’s Bio/Pharma Serialization and Traceability Summit to ensure a comprehensive, fully integrated and compliant serialization strategy and deployment while minimizing business operation disruptions.

Compelling Case Studies, Expert Panels
and Interactive Discussions:

  • Gain an in-depth update on the European and US Drug Supply Chain
    Security Act (DSCSA) and the Drug Tracing Pilot Programs
  • Employ strategies to drive business value from Serialization
    beyond compliance
  • Enhance your rollout roadmap for timely execution aligned with
    resources and key milestones to minimize operational disruptions
  • Identify implementation partners to achieve a successful rollout
    that is on time and within budget
  • Lessons learned from implementation — From planning to execution
  • Share best practices for compliant implementation of Serialization,
    including US DSCSA, EU and other countries
  • Assess strategies for meeting US and global regulations
    at the same time
  • Discover what you need to know to minimize the cost of
    compliance and maximize the return on your investment
  • Utilize data to drive specialty therapy revenue
  • Discuss forward-thinking approaches for leveraging data across sales,
    marketing and managed care to drive business performance and
    enhance the patient journey

Enhance your Experience with CBI’s
Co-Located Flagship Industry Meeting...

Validation Week banner